EN
HI

BROOKS LAB Share price

BROOKS

HealthcareSmall

135.31

0.56 (-0.41%)
NSE
BSE
Last updated on 20 May, 2025 | 15:31 IST
BUYSELL
Today's High

139.50

Today's Low

134.00

52 Week Low

73.25

52 Week High

198.86

The current prices are delayed, login to your account for live prices

Brooks Laboratories Chart

BROOKS LAB Share Key Metrics

Volume
16047.00
Market Cap
398.59 CR
LTQ@LTP
147@135.31
ATP
136.65
Var Margin
100 %
Circuit Range
129.07-142.66
Delivery %
0 %
Value
21.93 L
ASM/GSM
No
Market Lot
1

BROOKS LAB Futures & Options

Data Not Found

BROOKS LAB Corporate Actions

DateAgenda
2025-01-11-
DateEvent TypeAgenda
2025-01-11AGM/EGM-

BROOKS LAB News

Brooks Laboratories to make new investments in its JV with SteriScience Specialities

Jul 14 2021 16:35:58
Read More

About BROOKS LAB

NSE : 25140  
BSE : 533543  
ISIN : INE650L01011  

Our Company was incorporated vide a Certificate of Incorporation dated January 23 2002 bearing CIN No. U24232PB2002PLC24910 under the Companies Act 1956 with the name ?Brooks Laboratories Limited? by our promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. We received our certificate of commencement of business on February 19 2002 from the Registrar of Companies Punjab Himachal Pradesh & Chandigarh at Jalandhar. Our Company was initially promoted for manufacturing of latest molecules in Injectables tablets and dry syrups for the domestic customers. Our Company set up a facility for manufacturing Tablets Dry Syrup and Injectables which was supported by a research and development ("R&D") centre at Baddi Himachal Pradesh. Our Company started its commercial production in the month of June 2006. Our Company became profitable from the very first year of its production. This facility at Baddi is WHO-GMP and ISO 9001:2008 certified. The facility focuses on developing latest molecules in the niche segments and then selling it to various pharmaceutical marketing Companies. Before staring our company our promoters were engaged in manufacturing of Pharmaceutical Formulations in their partnership firm namely Brooks Pharmaceuticals. The firm had a manufacturing facility at F-94 Industrial Area Phase 7 Mohali Punjab. The factory at Mohali had annual installed capacity of 30 Lacs Injectables 300 Lacs Tablets and 15 Lacs Dry Syrups. Our promoters had a successful track record of running the manufacturing of formulations in the aforesaid firm profitably for over 6 years. In order to take an advantage of the growing market and avail the tax and other benefits that were made available by the Government to set up a manufacturing facility at Baddi our promoters decided incorporate our company Brooks Laboratories Ltd and set up a bigger and more sophisticated unit at Baddi in Himachal Pradesh. Subsequently the firm was dissolved in the month of December 2008. Further in years 2007 and 2008 to have a smooth transition from Brook Pharmaceuticals to Brooks Laboratories Ltd. Our Company paid/settled some dues to Creditors and Lenders of Brooks Pharmaceuticals aggregating to Rs. 151.79 Lacs. Later on to settle the above our Company purchased on book value certain assets (Fixed assets & Stocks) aggregating to Rs. 113.27 Lacs and received an aggregate sum of Rs. 38.52 Lacs from M/s. Brooks Pharmaceuticals a partnership firm promoted by our Promoters Mr. Atul Ranchal and Mr. Rajesh Mahajan. Key Events and Milestones January 23 2002Incorporation of Brooks Laboratories Limited. February 192002Received certificate for commencement of business May 5 2005Commenced setting up of manufacturing facility at Baddi Himachal Pradesh. April 102006 Manufacturing drugs license issued by the State Drugs Controlling and Licensing Authority HP. April 30 2005Commissioning of R&D centre at Baddi May 202006 Completion of Commissioning of plant for manufacture of Tablets capsules Injections Oral Liquids etc.May 30 2006Start of commercial production June 1 2006First PPI Formulation developed by the Company. October 272006 Obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. August 02 2007 Received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Limited Australia. April 30 2008* Takeover of some of the Assets of M/s Brooks Pharmaceuticals a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan by our Company. December 30 2008 Dissolution of M/s Brooks Pharmaceuticals a partnership firm of Our Promoters Mr. Atul Ranchal & Mr. Rajesh Mahajan. January 062009 Micro Small Medium Enterprise (MSME) Registration Certificate issued by Directorate of Industries for Manufacturing/Assembling Injections Capsules & Tabulates (Single Window Clearance Agency). April 72010 The manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health & Family Welfare HP. July 272010 Received an ISO 9001:2008 Certificate from UKAS Quality Management URS & IAF.

BROOKS LAB Management

NamePosition
Ms. Sonia Gupta Independent Director
Mr. Jitendra Pratap Singh Whole Time Director
Mr. Durga Shankar Maity Whole Time Director
Mr. Bhushan Singh Rana Whole Time Director
Mr. Lalit Mahajan Addnl.Independent Director
Read More

BROOKS LAB FAQs

The Buying Price of BROOKS LAB share is 135.31 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy BROOKS LAB share log in to your Choice trading account, or open a Choice Demat account, then add funds, search the company name, select your order type, and place your trade.

The Price-to-earnings (P/E) ratio of BROOKS LAB shares is 229.54. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio BROOKS LAB shares is 3.49. Useful to assess the stock's value relative to its book value.

To assess BROOKS LAB’s valuation compare Sector P/E, P/B which are 42.52 & 4.79 with sector averages, along with growth rates and financial metrics.

The Market Cap of BROOKS LAB is 398.59 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of BROOKS LAB share price is 198.86 & 73.25. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.